Yes, you can safely perform a head CTA with an eGFR of 29 mL/min/1.73 m²
With an eGFR of 29 mL/min/1.73 m², head CTA can be performed safely, as the risk of contrast-induced acute kidney injury from iodinated contrast is not significantly increased compared to non-contrast imaging, even at this level of renal function.
Evidence Supporting Safety
The concern about contrast nephrotoxicity in patients with eGFR <30 mL/min/1.73 m² has been substantially challenged by high-quality evidence:
Large propensity-matched studies show no significant difference in acute kidney injury rates between patients receiving iodinated contrast versus those who don't, even with eGFR <30 mL/min/1.73 m² 1. In a cohort of 12,508 matched patients stratified by kidney function, the odds ratio for AKI in patients with eGFR <30 was 0.97 (95% CI: 0.72-1.30, p=0.89), demonstrating no causal relationship between contrast exposure and kidney injury.
Recent stroke-specific data confirms this safety profile. In emergency stroke workups requiring CTA followed by cerebral angiography (sequential contrast exposure), postcontrast acute kidney injury occurred in only 9.5% of patients overall, with the highest risk in those with baseline eGFR <30 mL/min/1.73 m² 2. Critically, no fatal adverse effects were documented, and the authors concluded that patients suspected of stroke should be actively managed with respect to neurovascular function regardless of baseline renal function.
A 2026 study of contrast-enhanced CT brain in potential intraarterial therapy candidates found an overall PC-AKI incidence of only 0.89% 3. Remarkably, even in the CKD subgroup, mean eGFR actually improved by 8.67 mL/min/1.73 m² post-contrast.
Important Distinctions
Do not confuse iodinated contrast (used in CTA) with gadolinium-based contrast (used in MRA). The evidence you're asking about concerns iodinated contrast for CT:
- The ACR guidelines 4 note that while there are conflicting results for patients with eGFR <30 mL/min/1.73 m², the threshold of 30 mL/min/1.73 m² has the greatest level of evidence if a cutoff is used
- However, these older guidelines (2017) predate the more robust 2014 McDonald study 1 showing no independent nephrotoxic risk
The gadolinium guidelines 5 are irrelevant to your CTA question—those address MRI contrast and nephrogenic systemic fibrosis risk.
Practical Approach
For your patient with eGFR 29:
- Proceed with head CTA if clinically indicated (e.g., suspected stroke, vascular abnormality)
- Consider reduced iodine dose protocols if available, though standard dosing is acceptable
- Ensure adequate hydration if feasible
- The diagnostic benefit of timely vascular imaging far outweighs the minimal renal risk
Key Caveat
The one scenario requiring caution is acute kidney injury (AKI) superimposed on chronic kidney disease. If your patient's eGFR of 29 represents acute deterioration rather than stable CKD, exercise more caution and weigh the urgency of imaging more carefully. However, even in AKI, the evidence suggests contrast is not an independent nephrotoxic factor 1.